Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in PD-L1-Negative or Immunotherapy-refractory Esophagogastric Adenocarcinoma

NCT06340711 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT06340711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06340711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in PD-L1-Negative or Immunotherapy-refractory Esophagogastric Adenocarcinoma
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 2
Overall status
Recruiting
Start date
April 25, 2024
Completion date
April 30, 2030
Enrollment
27 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma